Get started
SUMMIT THERAPEUTICS INCSS

SUMMIT THERAPEUTICS INC

425.32MXND
−45.68−9.70%
At close at Feb 10, 18:20 GMT
MXN
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Forecast Seasonals

SMMT fundamentals

Key facts

Market capitalization‪266.37 B‬MXN
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−6.41MXN
Founded2003
Employees (FY)159
CEO—
Websitesmmttx.com
About

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Ownership
‪‪737.63 M‬‬
Closely held shares
‪‪622.70 M‬‬ (84.42%)
Free Float shares
‪‪114.92 M‬‬ (15.58%)
Closely held shares
‪‪622.70 M‬‬ (84.42%)
Free Float shares
‪‪114.92 M‬‬ (15.58%)
Capital structure
Market cap
‪‪266.37 B‬‬
Debt
‪‪150.49 M‬‬
Cash & equivalents
‪‪8.60 B‬‬
Enterprise value
‪‪257.91 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪266.37 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24

Growth and Profitability

Company’s recent performance and margins

Performance
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−1.40 B‬‬
‪‪−1.05 B‬‬
‪‪−700.00 M‬‬
‪‪−350.00 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−1.60 B‬‬
‪‪−1.20 B‬‬
‪‪−800.00 M‬‬
‪‪−400.00 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−1.40 B‬‬
‪‪−1.05 B‬‬
‪‪−700.00 M‬‬
‪‪−350.00 M‬‬
‪0.00‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
Actual
Estimate
Earnings
Next:May 8, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−2.00‬
‪−1.50‬
‪−1.00‬
‪−0.50‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

SMMT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−1.00 B‬‬
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬
‪‪3.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Assets
Liabilities